Oxbridge Re (NASDAQ:OXBR – Get Free Report) was upgraded by Zacks Research to a “hold” rating in a research report issued on Wednesday,Zacks.com reports.
OXBR has been the subject of several other research reports. Maxim Group cut their price objective on Oxbridge Re from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday. Weiss Ratings lowered Oxbridge Re from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 3rd. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Oxbridge Re has an average rating of “Hold” and an average target price of $3.00.
Check Out Our Latest Report on Oxbridge Re
Oxbridge Re Stock Performance
Oxbridge Re (NASDAQ:OXBR – Get Free Report) last released its earnings results on Saturday, February 14th. The insurance provider reported $0.02 earnings per share for the quarter. The firm had revenue of $0.58 million during the quarter. Oxbridge Re had a negative net margin of 76.47% and a negative return on equity of 33.33%. On average, sell-side analysts anticipate that Oxbridge Re will post -0.04 EPS for the current year.
Institutional Trading of Oxbridge Re
Institutional investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in shares of Oxbridge Re during the third quarter valued at approximately $32,000. Henrickson Nauta Wealth Advisors Inc. boosted its stake in Oxbridge Re by 100.0% during the fourth quarter. Henrickson Nauta Wealth Advisors Inc. now owns 137,400 shares of the insurance provider’s stock worth $185,000 after buying an additional 68,700 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Oxbridge Re in the 4th quarter valued at $39,000. Finally, J.W. Cole Advisors Inc. increased its holdings in Oxbridge Re by 106.1% in the 4th quarter. J.W. Cole Advisors Inc. now owns 68,000 shares of the insurance provider’s stock valued at $90,000 after buying an additional 35,000 shares during the period. Institutional investors and hedge funds own 5.64% of the company’s stock.
Key Stories Impacting Oxbridge Re
Here are the key news stories impacting Oxbridge Re this week:
- Positive Sentiment: Maxim Group reiterated a Buy rating on Oxbridge Re and kept a $3.00 price target, signaling upside versus recent trading levels. The firm’s updated estimates also suggest the company could return to profitability in some quarters, including $0.04 EPS for Q2 2026. MarketBeat OXBR analyst report
- Positive Sentiment: Oxbridge Re’s subsidiary SurancePlus reported that its tokenized reinsurance offerings delivered 29.3% and 43.4% annualized returns, beating original targets of 20% and 42%. That may support investor confidence in the company’s digital RWA/reinsurance strategy. SurancePlus exceeds return targets release
- Neutral Sentiment: Maxim Group’s broader forecast still shows a loss-making profile for Oxbridge Re over the next several periods, including estimated annual losses of $(0.04) in FY2026 and $(0.13) in FY2027. Those projections keep the turnaround story speculative. MarketBeat OXBR analyst report
- Negative Sentiment: Despite the bullish analyst target, the company’s recent estimates still call for multiple quarters of negative EPS, which may weigh on sentiment if investors focus on execution risk and the pace of earnings recovery. MarketBeat OXBR analyst report
Oxbridge Re Company Profile
Oxbridge Re Holdings Limited (NASDAQ: OXBR) is a reinsurance holding company that provides capital solutions and risk-sharing arrangements to insurance carriers. Its core business centers on offering treaty reinsurance and structured transactions designed to help insurers manage underwriting exposures and optimize their capital efficiency. By leveraging tailored financing structures, Oxbridge Re enables clients to transfer segments of their in-force life and health insurance portfolios, freeing up capital for growth or other strategic initiatives.
The company’s products and services include quota share reinsurance, coinsurance, and loss portfolio transfers, each crafted to address specific balance sheet and earnings targets of cedents.
Further Reading
- Five stocks we like better than Oxbridge Re
- How to Invest in the Biggest European Defense Surge in Decades
- The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&A
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
Receive News & Ratings for Oxbridge Re Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxbridge Re and related companies with MarketBeat.com's FREE daily email newsletter.
